For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$12.33
Thesis
Intellia Therapeutics is a leader in in vivo CRISPR editing, delivering gene edits directly inside the body rather than ex vivo. Its lead programs target large patient populations in amyloidosis and hereditary angioedema.
Catalysts
- Pivotal in vivo editing trial readouts
- Hereditary angioedema program advancement
- Platform expansion to additional in vivo targets
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 8OtherSEC
Intellia Therapeutics filed Form 8-K on 2026-09-08 covering items 7.01, 8.01 and 9.01.
- Sep 4DealSEC
8-K filed with items 1.01, 2.03, 7.01, 9.01 disclosing material definitive agreement and financial obligation.
- Aug 6Financial resultsSEC
Intellia Therapeutics filed 8-K (items 2.02, 9.01) reporting financial results.
- May 11Financial resultsSEC
8-K filing (items 2.02, 9.01) disclosing financial results.